Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Sumatriptan succinate 6mg injection solution 0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan succinate 12mg/mL injection solution 0.5mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan succinate 25mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Product containing precisely sumatriptan (as sumatriptan succinate) 100 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan 50mg rapid release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan 100mg rapid relase tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan (as sumatriptan succinate) 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Product containing precisely sumatriptan succinate 25 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Product containing precisely naproxen sodium 500 milligram and sumatriptan succinate 85 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan 4mg injection solution prefilled cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Sumatriptan 6mg injection solution prefilled cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
sumatriptan 12 mg/mL, seringue préremplie de 0,5 mL d'une solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
|
Product containing precisely sumatriptan (as sumatriptan succinate) 100 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Sumatriptan (as sumatriptan succinate) 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Product containing precisely sumatriptan succinate 25 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Product containing precisely sumatriptan succinate 25 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Product containing precisely naproxen sodium 500 milligram and sumatriptan succinate 85 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sumatriptan succinate |
Inferred relationship |
Some |
2 |
Product containing precisely naproxen sodium 500 milligram and sumatriptan succinate 85 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
2 |
Product containing precisely sumatriptan succinate 25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Product containing precisely sumatriptan (as sumatriptan succinate) 100 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Sumatriptan (as sumatriptan succinate) 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Product containing precisely naproxen sodium 500 milligram and sumatriptan succinate 85 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
2 |
Sumatriptan succinate 12 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |
Sumatriptan succinate 12 mg/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Sumatriptan succinate |
Inferred relationship |
Some |
1 |